Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug;148(5):391-393.
doi: 10.1161/CIRCULATIONAHA.123.065619. Epub 2023 Jul 31.

P-Selectin de-ACTIVation in COVID-19: What Have We Learned?

Behnood Bikdeli  1   2   3 , John W Eikelboom  4
Affiliations
Editorial

P-Selectin de-ACTIVation in COVID-19: What Have We Learned?

Behnood Bikdeli et al. Circulation. 2023 Aug.
No abstract available

Keywords: COVID-19; Editorials; P-selectin; crizanlizumab; inflammation; mortality; thrombosis.

PubMed Disclaimer

Conflict of interest statement

Disclosures Dr Bikdeli is supported by a Career Development Award from the American Heart Association and VIVA Physicians (#938814). Dr Bikdeli was supported by the Scott Schoen and Nancy Adams IGNITE Award and is supported by the Mary Ann Tynan Research Scientist award from the Mary Horrigan Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital, and the Heart and Vascular Center Junior Faculty Award from Brigham and Women’s Hospital. Dr Bikdeli reports that he is a consulting expert, on behalf of the plaintiff, for litigation related to 2 specific brand models of IVC filters. Dr Eikelboom holds the Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis and received honoraria or research support from Anthos, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Janssen, Merck, and Pfizer.

Comment on

References

    1. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:2950–73. - PMC - PubMed
    1. Libby P,Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41:3038–44. - PMC - PubMed
    1. Talasaz AH, Sadeghipour P, Kakavand H, Aghakouchakzadeh M, Kordzadeh-Kermani E, Van Tassell BW, Gheymati A, Ariannejad H, Hosseini SH, Jamalkhani S, et al. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;77:1903–21. - PMC - PubMed
    1. Ortega-Paz L, Galli M, Capodanno D, Franchi F, Rollini F, Bikdeli B, Mehran R, Montalescot G, Gibson CM, Lopes RD, et al. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021. - PMC - PubMed
    1. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399:143–51. - PMC - PubMed